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Angiomotin prevents pluripotent lineage
differentiation in mouse embryos via Hippo
pathway-dependent and -independent
mechanisms
Chuen Yan Leung1,2 & Magdalena Zernicka-Goetz1,2
Cell identity is speciﬁed in the early mammalian embryo by the generation of precursors for
two cell lineages: the pluripotent inner cell mass and differentiating trophectoderm. Here we
identify Angiomotin as a key regulator of this process. We show that the loss of Angiomotin,
together with Angiomotin-like 2, leads to differentiation of inner cell mass cells and com-
promised peri-implantation development. We show that Angiomotin regulates localization of
Yap, and Yap-binding motifs are required for full activity of Angiomotin. Importantly, we also
show that Angiomotin function can compensate for the absence of Lats1/2 kinases, indicating
the ability of Angiomotin to bypass the classical Hippo pathway for Yap regulation. In
polarized outside cells, Angiomotin localizes apically, pointing to the importance of cell
polarity in regulating Yap to promote differentiation. We propose that both Hippo pathway-
dependent and Hippo pathway-independent mechanisms regulate Yap localization to set
apart pluripotent and differentiated lineages in the pre-implantation mouse embryo.
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A
s development progresses, cell identity must be correctly
speciﬁed. In early mammalian development, three cell
types have to be set apart by the blastocyst stage: epiblast,
which will give rise to the embryo proper, trophectoderm (TE)
and primitive endoderm (PE), which will provide the extra-
embryonic structures such as the placenta and yolk sac.
Specifying these three cell lineages is mediated through three
waves of asymmetric cell divisions that start at the eight-cell stage
and generate nonpolar inside and polar outside cells1,2. Inside
cells constitute the so-called inner cell mass (ICM) and will
develop further as either the pluripotent epiblast or the PE, largely
depending on whether an inside cell is generated by the ﬁrst,
second or third wave of asymmetric division3,4. Outside cells will
progressively differentiate into TE. Thus, inside and outside cells
are progenitors for pluripotent ICM and TE lineages, respectively.
Three lines of evidence indicate that regulation of expression of
the transcription factor Cdx2 is particularly crucial to initiate
diversiﬁcation of ICM and TE lineages5–8. First, Cdx2 is the ﬁrst
transcription factor identiﬁed thus far whose expression becomes
restricted to the outside cells as soon as they form6, whereas
pluripotency factors are initially expressed in both inside and
outside cells. Second, Cdx2 downregulation leads to the
upregulation of pluripotency genes in outside cells and,
consequently, inhibition of TE formation and developmental
arrest5,6. Finally, experimental upregulation of Cdx2 in inside
cells prevents pluripotency of the ICM8.
The differential expression of Cdx2 between ICM and TE
progenitor cells is brought about along two major routes. We
recently found that one of these routes involves asymmetric,
apical localization of Cdx2 mRNA that results in outside cells
inheriting more Cdx2 mRNA than inside cells upon asymmetric
cell division6,8. Accordingly, preventing the asymmetric
localization and inheritance of Cdx2 mRNA leads to the
accumulation of Cdx2 protein in inside cells and, consequently,
inhibition of pluripotency genes such as Nanog8. In a second
route, transcriptional control is achieved through localization of a
transcriptional co-activator Yap, which permits Tead4-mediated
transcription of Cdx2 (ref. 9). In the polarized outside cells, Yap is
nuclear, whereas in inside non-polarized cells Yap is cytoplasmic.
This localization of Yap in mouse embryos is surprising because
in other model systems Yap is retained in the cytoplasm of
polarized cells, through the activity of apically associated proteins
such as Crumbs, Merlin, Expanded and Angiomotin (Amot)10–13.
This raises the question of whether, and if so how, cell polarity
might be involved in regulation of Yap localization in the mouse
embryo. To resolve this conundrum, it has been proposed that the
differential localization of Yap in the mouse is achieved through
differential Hippo signalling due to differences in the cell–cell
contacts between the inside and outside cells9. However, whether
there might be an alternative mechanism involved in controlling
Yap localization to regulate expression of differentiation genes
such as Cdx2 and lineage segregation in mouse development has
remained unknown.
Here we wished to elucidate further the mechanisms under-
lying the regulation of Cdx2 expression and the potential role of
cell polarity in affecting localization of Yap to control this
process. To this end, we chose to follow the role of Amot, a
protein known to bind to both tight-junction proteins and also to
Yap/Taz11–17. Amot is known to have an important role in a
variety of developmental process18,19, but any role for Amot in
the pre-implantation embryo has been unknown. Our results
indicate that cell polarity contributes to directing the localization
of Amot and of Yap in early mouse development. Importantly,
Yap localization and therefore Cdx2 expression is regulated not
only through a Hippo pathway-dependent mechanism but also
through a Hippo pathway-independent mechanism.
Results
Differential expression of Amot in ICM and TE precursors. To
determine the potential function of Amot in regulating cell-
lineage speciﬁcation in mouse embryos, we ﬁrst examined its
expression throughout pre-implantation development. Inter-
rogation of our previously generated genome-wide microarray
data set20 indicated that Amot expression rises from the four-cell
stage to peak at the early blastocyst stage. This prompted us to
analyse the localization pattern of Amot protein, using an
antibody that detects the C-terminal part of both p130 and p80
isoforms (Fig. 1). We were able to detect Amot protein from the
late eight-cell stage onwards when it becomes localized to the
membrane, consistent with Amot being a membrane-associated
protein21. However, when progenitors of the ICM and TE
lineages become set apart, at the 8- to 16-cell transition, Amot
becomes localized throughout the membrane in the inside cells,
whereas in outside cells it is restricted to the apical domain
(Fig. 1). As development progresses, Amot becomes highly
expressed in the ICM but barely detectable in the TE (Fig. 1).
These results indicate that Amot becomes expressed and localized
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Figure 1 | Amot expression and localization in pre-implantation embryos. Immunoﬂuorescent confocal images of Amot. Amot is ﬁrst detected at
the compacted eight-cell stage, where it is localized to the membrane (N¼ 16). At the 8- to 16-cell transition, Amot is localized apically in the
outside cells and throughout the membrane of the inside cells (N¼ 12). By the blastocyst stage, Amot is much more abundant in the ICM compared
with the TE (N¼ 18). Weak Amot staining can be seen on the apical domain of TE cells. Yellow areas and dotted lines mark inside cells. Scale bar, 10mm.
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differentially between the progenitors of the pluripotent ICM and
the differentiating TE lineages.
Amot is required to prevent differentiation of the ICM. To
determine the role of Amot, we used RNA interference (RNAi) to
speciﬁcally downregulate its expression from the zygote stage22.
Amot small interfering RNAs (siRNAs) were injected into the
zygote, together with Ruby mRNA as a marker of successful
injection, and developmental progression was compared with
embryos injected with control siRNA (Fig. 2a). Three different
siRNAs for Amot were injected and the siRNA resulting in the
highest knockdown efﬁciency (79.1±4% by qRT–PCR) (Fig. 2c)
was used in subsequent experiments. We also conﬁrmed Amot
depletion at the protein level (Fig. 2a). Amot depletion did not
prevent blastocyst formation (Fig. 2a) and did not affect total cell
number (Fig. 2b). However, we found that Cdx2, critical for TE
differentiation, was detectable not only in the TE but also within
the ICM in Amot-RNAi embryos (Fig. 2a). Overall, 61.8±5% of
total ICM cells in Amot-RNAi blastocysts were clearly expressing
Cdx2, as compared with 5.0±2% in control embryos (Fig. 2b). As
we observed that the absence of Amot leads to Cdx2 expression in
the ICM, we examined the localization of the co-activator of Cdx2
expression, Yap9. We found Yap to be localized to the nuclei of
ICM cells upon Amot-RNAi (Fig. 2a). Amot depletion also led to
the expression of other TE-marker genes such as Eomes and Ck-8
(Troma-1) in the ICM (Fig. 2a). The use of an siRNA control,
together with rescue experiments (described later), indicate that
the Amot-RNAi phenotype is speciﬁc and not an artefact of either
microinjection or off-target effects.
We next wished to determine the consequences of Amot-RNAi
on pluripotency factors. qRT–PCR of Amot-RNAi blastocysts
revealed that the transcript levels of Oct4, Nanog and Sox2 were
signiﬁcantly reduced to 38.5±11%, 29.8±2% and 17.4±5%,
respectively (Po0.05, Student’s t-test) (Fig. 2c), although Oct4
and Nanog proteins were still detectable (Fig. 2a). In contrast,
and in agreement with our earlier analyses, the transcript levels
of Cdx2 and Eomes increased to 214.9±18% and 281.0±19%
of control levels, respectively, whereas Gata3, another TE-marker
gene, was not signiﬁcantly elevated (Fig. 2c). Together, these results
suggest that, in the absence of Amot, although cells can be allocated
to the ICM, they express TE-speciﬁc genes and the pluripotency
network (Oct4, Nanog and Sox2) becomes suppressed.
Amot acts in a cell-autonomous manner. As Amot localizes to
membranes, we wondered whether it might be able to signal
and affect the fate of neighbouring cells. To investigate this, we
injected Amot siRNA into one blastomere at the late two-cell
embryo, co-injecting Ruby mRNA as a lineage marker, and
analysed embryo development at the blastocyst stage. We found
that the Amot-depleted clones contributed to both inside
(53.3±1%) and outside (46.7±1%) cells, suggesting that the cell
allocation process per se was unaffected. In all embryos, only the
clones of Amot-depleted cells were expressing Cdx2 in the ICM
(Fig. 2d), suggesting that loss of Amot in one cell does not affect
a neighbouring cell, and therefore Amot regulates cell fate in a
cell-autonomous manner.
Amot overexpression is insufﬁcient to drive cells to ICM. After
establishing that Amot is necessary for correct ICM speciﬁcation,
we sought to determine whether Amot is sufﬁcient to induce
pluripotent ICM fate when overexpressed. To examine this,
we injected p130-Amot mRNA into one blastomere at the late
two-cell embryo, co-injecting Ruby mRNA as a marker (Fig. 2e).
We conﬁrmed Amot overexpression by immunoﬂuorescence
(Supplementary Fig. S1). Analysis of cell allocation revealed that
the Amot overexpressing clone contributed to both ICM
(46.8±2%) and TE (53.2±2%) lineages, suggesting that Amot is
insufﬁcient to drive cells into the ICM. Interestingly, by the
blastocyst stage, Amot remained highly expressed only in the
ICM and markedly downregulated in the TE (Supplementary Fig.
S2), pointing to a potential regulatory mechanism in the TE that
degrades Amot to prevent incorrect fate speciﬁcation.
Depletion of Amot with Amotl2 enhances ICM differentiation.
Our results indicate that the lack of Amot leads to the expression
of differentiation genes within the ICM and downregulation of
pluripotency. It has been reported that Amot / embryos can
progress beyond implantation18,19, prompting us to test whether
Amot-related proteins might be able to compensate for Amot
function. Amot belongs to the motin family that contains two
other members: Amot-like 1 (Amotl1) and Amot-like 2 (Amotl2)
(Fig. 3a)23, both of which have overlapping functions with
Amot11–13,24. To eliminate all three motins, we injected Amot,
Amotl1, Amotl2 siRNAs into zygotes and examined develop-
mental progression. We conﬁrmed knockdown by qRT–PCR:
Amot transcripts were depleted to 21.6±3% and Amotl2 to
19.6±3%, whereas Amotl1 transcripts were undetectable
(Fig. 3c). We found that co-depletion of Amot and Amotl2
permitted blastocyst formation (9/10, 90%; control siRNA: 9/10,
90%) and did not affect the total cell number or number of ICM
cells per embryo (Fig. 3b). Strikingly, however, the proportion of
Cdx2-expressing cells within the ICM was much higher in the
combined motin-RNAi embryos than upon depletion of Amot
alone. Nearly all (98.0±1%) ICM cells of the Amot- and Amotl2-
RNAi embryos were Cdx2 positive compared with the 61.8±5%
of Amot only-RNAi and 5.0±2% of control embryos (Fig. 3b,d).
This suggests that Amot and Amotl2 both function to suppress
Cdx2 expression in the ICM.
Amot depletion compromises developmental potential. To
determine whether the ICM differentiation caused by the loss of
Amot would affect development in vivo, Amot-RNAi and Amot,
Amotl1, Amotl2-RNAi embryos were transferred into pseudo-
pregnant surrogates to assess their developmental potential
(Supplementary Table S1). siRNAs were injected into both blas-
tomeres at the two-cell stage, rather than the zygote, to prolong
the RNAi effect (Fig. 4a). GFP transgenic embryos injected with
control siRNA were used as transfer controls to normalize for
transfer efﬁciency in different recipients. After injection, the
embryos were cultured to the blastocyst stage and sampled to
conﬁrm their respective phenotypes (Fig. 4b). To assess for suc-
cessful development beyond implantation, the embryos were
recovered at E7.5 (Fig. 4c). After normalizing for the transfer
efﬁciency of the different recipients and background of the
embryos, we found that 100% of the control-RNAi embryos
progressed successfully to E7.5, compared with 32.7% of Amot-
RNAi embryos (Po0.05, w2-test, compared with control) and
27.8% of the combined motin-RNAi embryos (Po0.05, w2-test,
compared with control). There was no signiﬁcant difference
between the developmental success of Amot-RNAi and combined
motin-RNAi embryos (P¼ 0.67, w2-test), although loss of all three
motins might lead to a more severe outcome (Supplementary
Table S2). Overall, our result suggests that loss of Amot com-
promises development, potentially as a result of a more differen-
tiated ICM, signifying an important role for Amot in early mouse
development.
p130-Amot is the isoform involved in cell fate regulation. The
Amot protein is expressed as two isoforms, p80 and p130
(refs 21,25). The p130 isoform has a unique N-terminal extension
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and the rest of the protein is identical to the p80 isoform (Fig. 5a).
To determine which isoform is required for the ﬁrst cell lineage
speciﬁcation, we depleted Amot with a dsRNA targeting the
30-UTR in the zygote and then attempted to rescue Amot-RNAi
effect with either the p80- or p130-Amot isoforms at the eight-cell
stage. Successful knockdown by the dsRNA was conﬁrmed by
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qRT–PCR (Supplementary Fig. S3). For the rescue, we co-injected
either p80- or p130-Amot mRNA, with Ruby mRNA as a marker,
into 2–3 blastomeres at the eight-cell stage. To quantify the extent
of the rescue, we determined the percentage of the Ruby- and
Cdx2-positive cells in the ICM (Fig. 5b). In control blastocysts,
12.6±5% of the Ruby-marked ICM cells were Cdx2-positive
(Fig. 5c) (most likely owing to inherited Cdx2 protein from an
outside mother cell). This value increased signiﬁcantly (Po0.05,
Student’s t-test) to 88.7±4% of the Amot-RNAi/Ruby-expressing
embryos (Fig. 5c). When we injected p130-Amot mRNA to the
Amot-RNAi embryos, the proportion of Cdx2-expressing cells
in the ICM dropped signiﬁcantly to 17.4±7%. This value was
signiﬁcantly different (Po0.05, Student’s t-test) from Amot-
RNAi/Ruby-expressing embryos and not signiﬁcantly different
from control embryos (P¼ 0.84, Student’s t-test), indicating that
p130-Amot is able to fully rescue the effects of Amot depletion.
We found that providing p80-Amot into Amot-RNAi embryos
still resulted in 71.2±7% of ICM cells expressing Cdx2, which
was signiﬁcantly different from the control embryos (Po0.05,
Student’s t-test) (Fig. 5b,c). Therefore, the Amot-RNAi effect can
be rescued only by the p130 isoform, indicating that p130-Amot
function is required to suppress the differentiation pathway in
the ICM.
Yap-binding motifs are involved in Amot function. The
N-terminal extension of the p130-Amot contains two PPxY
motifs. Mutating the tyrosine residues to alanine in the PPEY
motifs abolishes the Yap-binding ability of Amot and its ability to
tether Yap in the cytoplasm11–13. A third motif conserved across
all motins, LPTY, has been suggested to mediate interaction
between Yap and Amotl1 (ref. 26). These motifs therefore
represent a Yap-dependent but Hippo pathway-independent
activity of Amot. We sought to determine whether Amot might
function in the mouse embryo independently of the Hippo
pathway. We hypothesized that if overexpression of the triple
motif mutant (Y110/243/288A) could rescue the Amot-depletion
phenotype, Yap-binding motifs are consequently not important.
If the opposite is true, it would follow that Amot functions
through a Hippo pathway-independent, Yap-binding mechanism.
To test this, we depleted Amot, from the zygote as before, and
subsequently injected mRNA for Y110/243/288A Amot with
Ruby mRNA as a lineage marker, into 2–3 blastomeres at the
eight-cell stage. We found that, at the blastocyst stage, 42.0±7%
of the clonal Ruby-positive ICM cells were expressing Cdx2
(Fig. 5c), which was signiﬁcantly lower than that in Amot-RNAi
embryos (88.7±4%, Po0.05). This suggests the Yap-binding
motifs are required for the full activity of Amot, and therefore
Amot function is, in part, Yap binding dependent. In agreement
with this, Yap staining in Amot overexpressing embryos suggests
possible co-localization between Yap and Amot (Supplementary
Fig. S4), as previously shown in MCF10A cells11. In some
embryos (Fig. 5c, panel v), however, Cdx2 was not detectable in
the ICM upon the Y110/243/288A mutant overexpression,
suggesting that the mutant Amot was partially able to suppress
Cdx2 expression. Indeed, the proportion of Ruby- and Cdx2-
positive ICM cells following injection of mRNA for Y110/243/
288A Amot was 42.0±7%, an intermediate value between 17.4±
7% of the control and 88.7±4% of the Amot-RNAi embryos
(Fig. 5c). These results indicate that the Yap-binding sites are
required for the full activity of Amot, raising the possibility
that pluripotent lineage speciﬁcation can be regulated in a Yap-
binding-dependent but a Hippo pathway-independent manner.
Amot compensates for Lats1/2 function. The above results
opened up a possibility that Amot can regulate Yap localization,
and consequently Cdx2 expression, independently of the Hippo
pathway. If this is the case, Amot overexpression should suppress
Cdx2 expression in the absence of Hippo pathway kinases, Lats1/
2, which phosphorylate Yap to prevent its nuclear localization9.
To directly test this, we eliminated Lats1 and Lats2 transcripts by
injecting zygotes with Lats1/2 siRNAs and, at the eight-cell stage,
injected 2–3 blastomeres with either Ruby mRNA only or p130-
Amot mRNA with Ruby mRNA. We veriﬁed successful depletion
of Lats1/2 by qRT–PCR (Supplementary Fig. S5). On assessing at
the morula stage, we found that Lats1/2-RNAi/Ruby-expressing
embryos had 35.7±6% of Ruby-positive inside cells expressing
Cdx2, which was signiﬁcantly more than the 5.9±4% in control-
RNAi/Ruby-expressing embryos of the same stage (Po0.05,
Student’s t-test), in agreement with previous report9. Importantly,
overexpression of Amot following Lats1/2 depletion signiﬁcantly
decreased the proportion of Cdx2- and Ruby-positive inside cells
to 18.2±4% (Fig. 5c), compared with Lats1/2-RNAi/Ruby-
expressing embryos (Po0.05, Student’s t-test). This value was
not signiﬁcantly different from the control-RNAi/Ruby-express-
ing embryos (P¼ 0.06, Student’s t-test). These results suggest
that by increasing the amount of Amot its Hippo pathway-
independent activity can compensate for the loss of the Hippo
pathway kinase Lats1/2.
To conﬁrm this conclusion, we next overexpressed Y110/243/
288A Amot that cannot bind Yap in the Lats1/2-RNAi back-
ground. To this end, we depleted Lats1/2 as above, but now
co-injected Y110/243/288A Amot, with Ruby mRNA as a lineage
Figure 2 | Amot prevents differentiation of the ICM. (a) Immunoﬂuorescent confocal images of TE/ICM marker genes of control and Amot-RNAi
blastocysts. Control (N¼ 20)/Amot siRNA (N¼ 30) were injected into zygotes and cultured to blastocysts; Amot protein was undetectable in Amot-RNAi
blastocysts. In the absence of Amot, TE markers Cdx2 (N¼ 30), Eomes (N¼ 16) and Ck-8 (antibody: Troma-1) (N¼ 16) become upregulated in the ICM
and Yap localized to the nuclei of ICM cells (N¼ 12) in contrast to control blastocysts, where Yap is cytoplasmic (N¼ 12). Pluripotency markers Oct4 and
Nanog (N¼ 11) are still visible. Yellow areas and dotted lines mark inside cells. Scale bar, 10 mm. (b) Total cell number of Amot-RNAi versus control
blastocysts. The total number of cells between Amot-RNAi (46.3±2cells, N¼ 20 embryos) and control blastocysts (43.2±2cells, N¼ 30 embryos) is
not signiﬁcantly different (P¼0.51, Student’s t-test). The percentage of Cdx2-positive cells in the ICM of Amot-RNAi blastocysts (61.8±5%, N¼434 cells,
30 embryos) is greater than in control blastocysts (5.0±2%, N¼ 311 cells, 20 embryos). Error bars represent s.e.m.. Student’s t-test was used to
test signiﬁcance. (c) qRT–PCR of whole embryos, comparing expression levels of several TE/ICM markers of Amot-RNAi (N¼60) versus control
(N¼60) blastocysts. Error bars represent s.e.m. Student’s t-test was used to test signiﬁcance. (d) Immunoﬂuorescence of embryos clonally depleted
of Amot, showing that Amot governs cell fate in a cell-autonomous manner. One blastomere of two-cell embryos was injected with control/Amot siRNA
and Ruby mRNA, and cultured to blastocysts. Ruby-positive cells mark the injected clone. In the ICM of the mosaic Amot-RNAi embryos, only the
Ruby-positive cells expressed Cdx2 (N¼ 21 cells) (arrows). Yellow areas mark the ICM. Dotted lines mark Ruby-positive ICM cells. Scale bar, 10 mm.
(e) Immunoﬂuorescence of embryos that are clonally overexpressing Amot, showing that Amot is not sufﬁcient to drive cells to ICM. One blastomere
of two-cell embryos was injected with Ruby mRNA only or Amot and Ruby mRNA, and cultured to blastocysts (N¼ 10). Ruby-positive cells mark the
overexpressing clone. Yellow areas mark the ICM. Dotted lines mark Ruby-positive cells. Scale bar, 10mm.
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tracer, to 2–3 blastomeres at the eight-cell stage. In these
embryos, 41.4±8% of the Ruby-positive inside cells were Cdx2
positive, a value not signiﬁcantly different from the 35.7±6% of
the Lats1/2-RNAi/Ruby-expressing embryos (P¼ 0.58, Student’s
t-test) (Fig. 5c). Thus, the Y110/243/288A mutant is not able to
compensate for the loss of Lats1/2, further pointing to a direct
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Figure 3 | Co-depletion of motin family members enhance ICM differentiation. (a) The motin family proteins with key regions outlined. (b) Total cell
number and ICM cell number are not signiﬁcantly different between control (N¼ 21), Amot-RNAi (N¼ 31) and Amot; Amotl1; Amotl2-RNAi (N¼ 12)
blastocysts. However, in the triple motin-RNAi embryos, 98.0±1% of ICM cells of the triple RNAi embryos were Cdx2 positive at the blastocyst stage
(N¼ 210 cells, 12 embryos) compared with the 61.8±5% of Amot-RNAi (N¼434 cells, 30 embryos) and 5.0±2% of control embryos (N¼ 311 cells,
21 embryos). Error bars represent s.e.m. Student’s t-test was used to test signiﬁcance. (c) qRT–PCR of whole embryos, comparing expression levels of
Amot and Amotl2 in control embryos (N¼ 21) and triple knockdown embryos (N¼ 21). Amot and Amotl2 were downregulated to 21.6±3% and
19.6±3%, respectively, relative to control levels. Amotl1 expression could not be detected. Error bars represent s.e.m. Student’s t-test was used to
test signiﬁcance. (d) Z-section series of immunoﬂuorescent confocal images of control, Amot-RNAi (N¼ 30) and Amot; Amotl1; Amotl2-RNAi (N¼ 12)
blastocysts, with the highest proportion of Cdx2-expressing cells in the triple knockdown. Dotted lines outline the ICM. Scale bar,: 10mm.
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Amot/Yap interaction that bypasses the classical Hippo pathway. On
a side note, this also indicates that the Lats1/2 phenotype is Yap
dependent, as only Amot with intact Yap-binding sites can compen-
sate for Lats1/2 function. Taken together, these results further
indicate that Amot can function in a Yap-dependent but Hippo
pathway-independent manner to specify cell fate in the mouse
embryo.
Discussion
Analyses of spatial and temporal expression patterns together
with the downregulation and overexpression studies we present
here identify Amot as a new important regulator of the ﬁrst cell
fate speciﬁcation in the mouse embryo. We ﬁnd that Amot
becomes enriched in the ICM versus TE progenitor cells as
development progresses; Amot is critical to prevent expression of
TE-marker genes in the pluripotent lineage; ICM differentiation
is signiﬁcantly enhanced by co-depletion of Amot with Amotl2;
Amot regulates localization of Yap; full activity of Amot is
dependent on the Yap-binding motifs, suggesting a Hippo
pathway-independent function; Amot function can compensate
for the absence of Lats1/2, supporting its ability to function
independently of the Hippo pathway; and mutating the Yap-
binding motifs affects, but does not completely abolish, Amot
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Figure 4 | Loss of AMOT compromises the developmental potential of peri-implantation embryos. (a) Experimental outline: siRNA was injected
to both blastomeres of two-cell-stage embryo, cultured to E3.5 and transferred to 2.5 dpc pseudo-pregnant recipients. The embryos were recovered
5 days later at E7.5. Embryos were injected with either control siRNA, Amot siRNA or a combination of Amot, Amotl1 and Amotl2 siRNA. For each of the
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expressed CDX2 in the inside cells, whereas in GFP (N¼ 10) and WT (N¼ 10) embryos injected with control siRNA CDX2 expression was restricted
to the outside cells. (c) The outcome of the embryo transfers. To assess for developmental success, the embryos were recovered at E7.5. For the
control-RNAi group, out of the 40 embryos transferred, 38 embryos were recovered, of those 20 (100%) were GFPþ and 18 (90%) were GFP .
For Amot-RNAi, out of 40 embryos transferred, 22 embryos were recovered, of those 17 (85%) were GFPþ and 5 (25%) were GFP . For the Amot;
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embryos (Po0.05, w2-test, compared with control). There was no signiﬁcant difference between the developmental success of Amot-RNAi and Amot;
Amotl1; Amotl2-RNAi embryos (P¼0.67, w2-test). Scale bar, 100mm.
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activity, suggesting that Amot might also act through an
alternative mechanism, such as through activating Lats1/2
via the Hippo pathway or independent of Yap and, ﬁnally, that
Amot depletion, together with depletion of Amotl2, results
in compromised development at peri-implantation stages.
Overall, our results identify a role of Amot in the ﬁrst-lineage
speciﬁcation to prevent an inappropriate cell fate program in the
pluripotent ICM and suggest that Amot has two distinct roles
in this process, sequestering Yap, which is Hippo pathway
independent, and also activating the Hippo pathway kinase
Lats1/2 (Fig. 6).
Our results indicate that loss of Amot results in the
upregulation of genes that promote differentiation and, conse-
quently, downregulation of pluripotency genes such as Oct4,
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Nanog and Sox2 in the ICM. Despite this, we observe that some
pluripotency-associated transcription factors are still present,
possibly as a result of pre-existing protein. This ﬁnding is likely to
explain why Amot / embryos can survive through implanta-
tion and arrest only at early post-implantation stages18,19. This
could also be due to developmental plasticity, as the mouse
embryo has been shown to require establishment of only four
pluripotent cells by implantation to support its development to
birth4. Finally, genetic redundancy could also be a contributing
factor, as we show here that simultaneous depletion of Amot and
Amotl2 lead to a much stronger phenotype than depletion of
Amot on its own.
As development progresses, Amot becomes upregulated in
ICM but not TE progenitors. A deep sequencing analysis of global
gene expression patterns between ICM and TE progenitors after
the ﬁrst wave of asymmetric division, at the 16-cell stage, reveals
similar levels of Amot mRNA (Krzysztof Wicher, Sarah Graham
and Magdalena Zernicka-Goetz, unpublished observations).
Although this does not rule out differential transcription later,
our results suggest that Amot enrichment in the ICM might
result from differential stability of the protein between ICM
and TE cells. In support of this, we show that when Amot
is overexpressed, it is downregulated in TE but not in ICM
cells (Supplementary Fig. S2). Moreover, one of the E3 ubiquitin
ligases able to promote Amot degradation27, NEDD4L, is expres-
sed two-fold higher in TE than in ICM progenitors (Krzysztof
Wicher, Sarah Graham and Magdalena Zernicka-Goetz,
unpublished observations), thus giving the potential of reducing
Amot levels in TE. In addition, cytoplasmic Yap has been found
to protect Amotl1 from NEDD4-mediated degradation26, raising
an interesting possibility that Yap could act in a positive feedback
loop to prevent Amot degradation in the ICM.
Two models are often considered for the ﬁrst cell fate
decision in the mouse embryo. The polarity model1 stresses the
importance of cell polarity in directing cell fate, and the positional
model28,29 stresses the importance of cell position. It has
been demonstrated that cell polarity and cell position re-enforce
each other30, and these two models can be brought together
conceptually31. Identifying Amot as a cell fate regulator is a
molecular step towards this uniﬁcation, because it lends support
to both: Amot becomes enriched in inside but not outside
cells (supporting a positional ‘inside-outside’ model) and its
localization is polarized in outside cells (supporting a ‘polarity’
model). Apically localized Amot in polarized outside cells may
interact with polarity factors, and, in support of this idea, it has
been already shown to associate with tight-junction proteins via
its PDZ-binding domain14–17. Therefore, we would like to suggest
that, in the mouse embryo, as in other model systems, cell
polarity is involved in Yap regulation as it can, for example,
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Figure 6 | Hippo pathway-dependent and -independent mechanisms
in lineage segregation. The results we present here show that Amot
becomes enriched in the ICM as cell lineages become progressively
established, and that Amot functions to prevent differentiation of the
pluripotent lineage. Our results suggest that Amot acts through two routes
to prevent ICM differentiation, of which one is dependent and another is
independent of the Hippo pathway. The Hippo pathway-independent
(Lats1/2–independent) mechanism is likely to involve Amot’s ability
to tether Yap to the cytoplasm/membrane, as we ﬁnd that Yap-binding
motifs of Amot are essential for its full activity. But, it can also involve
Amot interacting with actin/cell polarity molecules. The Hippo pathway-
dependent mechanism is likely to involve Amot’s role in activating
Lats1/2 (as shown in24) to allow phosphorylation of Yap, which prevents
its transition to the nucleus9. In agreement, we ﬁnd that mutation of
the Yap-binding sites does not completely abolish the activity of Amot.
Combined, this results in Yap being sequestered from the nucleus
and therefore the expression of TE-genes, such as Cdx2, is switched off
and the ICM pluripotency maintained. In contrast, in TE cells, most of
Amot is degraded and the remaining Amot is sequestered to the apical
domain. We hypothesize that in this location Amot is shielded from
binding Yap through its interactions with F-actin and/or polarity factors.
In agreement with this hypothesis, Amot is reported to associate with
actin32 and tight-junction proteins via its PDZ-binding domain in tissue
culture cells14–17. This suggests that cell polarity is involved in allowing
Yap to translocate to the nucleus to act, together with Tead4, to stimulate
Cdx2 expression and TE differentiation.
Figure 5 | p130-Amot functions independently of the Hippo pathway kinases Lats1/2. (a) Amot constructs with key regions outlined. The p80- and
p130-Amot isoforms are identical, except the p130 isoform has an N-terminal extension, which contains three Yap-binding motifs. (b) Eight sets of
experiments (i)–(viii) are shown, which follow the same experimental outline: siRNA/dsRNA was injected into the zygote and mRNA was injected into
two or three blastomeres at the eight-cell stage. Cdx2-positive inside cells from all eight sets of experiments were counted manually. The phenotype
was quantiﬁed by calculating the percentage of Cdx2-positive cells from the Ruby-positive inside cells at the blastocyst stage (or the morula stage
in the case of Lats1/2 knockdown). Panels show confocal images of representative embryos from each set of experiments. Dotted lines mark Ruby-positive
inside cells. Scale bar, 10mm. (c) Combined quantiﬁcations from the experiments outlined in (b). Number of biological replicates: (i) N¼41 cells, 15
embryos; (ii) N¼96 cells 34 embryos; (iii) N¼ 53 cells, 35 embryos; (iv) N¼44 cells, 11 embryos; (v) N¼ 20 cells, 40 embryos; (i) N¼ 22 cells, 9
embryos; (vi) 139 cells, 24 embryos; (vii) N¼ 145 cells, 43 embryos; (viii) N¼ 58 cells, 18 embryos. Error bars represent s.e.m. This quantiﬁcation shows
that the p130, but not the p80, isoform is able to rescue the Amot phenotype and the Yap-binding motifs are required for the full activity of p130-Amot.
Lats1/2 depletion leads to an increased Cdx2-positive inside cell number, but overexpression of p130-Amot is able to prevent Cdx2 expression in the
absence of Lats1/2, demonstrating a Hippo pathway-independent mechanism. Conﬁrming this conclusion overexpressing the Amot mutant for Yap-binding
motifs in a Lats1/2-RNAi background does not affect the Lats1/2 phenotype.
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inhibit Amot’s ability to bind Yap to restrain its translocation to
the nucleus (Fig. 6).
The ability of Amot to function through Yap is strongly
suggested by the three putative Yap-binding motifs of p130-Amot
that are absent in p80-Amot and which we show here are
essential for the full activity of Amot. Indeed, Yap seemingly co-
localizes with p130-Amot when p130-Amot is overexpressed
(Supplementary Fig. S4). Another way to test Amot’s Yap
dependence would be through an Amot; Yap double knockdown.
However, interpreting such an experiment would be difﬁcult
because of the redundancy of Yap with its homologue Taz9
(Supplementary Fig. S6).
We ﬁnd that Amot is partly functional following mutation of
its Yap-binding sites, which suggests that two possible mechan-
isms of Amot function are tenable. One would reﬂect the direct
interaction between Amot and Yap, independent of the Hippo
pathway. The second would reﬂect the residual function of this
Yap-binding defective Amot mutant that would still be able to
activate Lats1/2, leading to Yap phosphorylation and cytoplasmic
retention (as demonstrated in HEK293 cells24). Our results
cannot also rule out the possibility that the residual function
of this Amot mutant reﬂects function that is entirely independent
of Yap.
The key regulatory domain of Amot appears to be its
N-terminal part, as we show that the p80 isoform does not have
a role in cell fate regulation. This N-terminal domain could be
responsible for activation of Lats1/2-dependent phosphorylation
of Yap, as supported by in vitro data24. We also consider
the actin-binding properties of the N-terminal domain of p130-
Amot32 could relate to its ability to suppress Cdx2 expression in
the pluripotent lineage. In agreement with this hypothesis, it has
been reported that an increase in ﬁlamentous actin results in
increased nuclear Yap and activation of Yap target genes33–38.
Finally, we show that overexpressing p130-Amot prevents the
expression of Cdx2 in inside cells lacking Lats1/2. Hence, in the
absence of the Hippo pathway, high levels of Amot are sufﬁcient
to sequester most of the Yap molecules from the nucleus. Taken
together, our results suggest that both Hippo pathway-dependent
and -independent processes are involved in regulating Yap
localization to generate pluripotent cells in the mouse embryo.
Methods
Embryo collection and culture. Animals were maintained in the Animal Facility
of Gurdon Institute at 12:12 light cycle and provided with food and water
ad libitum. All experiments were conducted in compliance with Home Ofﬁce
regulations. For embryo collection, 4- to 6-week-old F1 generation mice from the
C57Bl6 and CBA strains were superovulated with 10 IU of pregnant mare serum
gonadotropin (PMSG; Intervet) and 10 IU human chorionic gonadotropin
(hCG; Intervet) 48 h later and mated with F1 (C57Bl6CBA) male mice. Embryos
were dissected out of the oviducts into M2 medium. For zygote recovery, cumulus
cells were removed by hyaluronidase treatment (1mgml 1 in M2). Embryos were
cultured in drops of KSOM media (Millipore) under parafﬁn oil in 5% CO2 at
37 C.
Immunohistochemistry and analysis. Embryos were ﬁxed in 4% PFA for 20min
and washed twice for 5min in PBS-T (PBS with 0.1% Tween). They were then
permeabilized with 0.5% Triton X-100 in PBS for 20min and washed three times
for 5min in PBS-T. The embryos were incubated with primary antibodies diluted
in 3% BSA (Sigma) for 1 h. Cdx2 antibody (Biogenex) was used at a dilution of
1:200; Oct4 antibody (Santa Cruz) at 1:200; Nanog antibody (2BScientiﬁc) at 1:200;
Yap antibody (Santa Cruz) at 1:400; Eomes antibody (Abcam) at 1:250; Troma-1 at
1:100; and Amot antibody (Santa Cruz) at 1:2,000. The embryos were then washed
three times for 5min in PBS-T. Secondary antibodies (Invitrogen, AlexaFluor) and
DAPI (Invitrogen) were applied for 1 h at a dilution of 1:400 in 3% BSA (Sigma).
After washing three times for 5min in PBS-T, the embryos were washed overnight
in M2 medium. Embryos were imaged on glass-bottom dishes rather than on slides
in order to avoid ﬂattening the embryo. Confocal images were captured with a
Leica SP5 confocal microscope with a Z-resolution of 4 mm. All images are layer-
normalized using IMARIS to account for signal intensity differences from different
sections. To count total cell numbers, DAPI was used as a nuclear marker to
represent each cell. Acquisition of Cdx2 stainings for cell counting was performed
using identical settings on a Leica SP5. To count Cdx2-positive cells, the confocal
z-stacks were ﬁrst exported to IMARIS and layer-normalized using the built-in
function. The normalized sections were then assessed for the presence of Cdx2
signal. Any nuclei with signal detectable by eye were scored as ‘Cdx2 positive’.
Cells were then manually counted in ImageJ using the MTrackJ plug-in. Student’s
t-test, unless otherwise stated, was used to test statistical signiﬁcance.
RNAi reagents and construct preparation. p130- and p80-Amot were cloned
from mouse kidney cDNA and sequence veriﬁed. mRNA was synthesized using the
mMESSAGE mMACHINE Kit (Life Technologies). dsRNA was designed and
evaluated using E-RNAi, a web application for the design of RNAi reagents39.
The DNA template of the dsRNA was ampliﬁed from mouse kidney cDNA,
and dsRNA was synthesized from DNA using the T7 MEGAscript kit (Life
Technologies). The dsRNA was annealed by heating to 70 C for 5min and allowed
to cool at room temperature for 2 h. It was treated with RNAse T1/A and
Proteinase K to remove ssRNA and proteins. Site-directed mutagenesis of the PPxY
motifs was performed via overlap extension PCR. Four PCR fragments were
ampliﬁed from Amot DNA using mutagenic primers, with two fragments
overlapping over each PPxY motif. All four fragments were pooled, annealed and
PCR ampliﬁed into one complete piece of DNA, which was sequence veriﬁed.
The following is the sequence of Amot siRNA used: 50-CAGGAGAAGCCTACTCA
GCTA-30 . Primers used for cloning are as follows: p80-Amot 50-TTTTTGGAT
CCACCATGCCTCGGGCTCAG-30 50-TTCGTTTGCGGCCGCTTAGATGAGA
TATTCC-30 ; p130-Amot 50- TTTTTTTTTTGGATCCACCATGAGAAGTTCT
GACGATCAGCC-30 50-TTTTTTTTTTGCGGCCGCTTAGATGAGATATTC
CACC-30 . The following primers were used to generate the p130-Amot
Y110/243/288A mutant: 50-TTTTTTTTTTGGATCCACCATGAGAAGTTCTG
ACGATCAGCC-30 ; 50-GACCTTGGCCTCTTCGGCGGTTGGGAGTTCTTC-30 ;
50-GAAGAACTCCCAACCGCCGAAGAGGCCAAGGTC-30 ; 50-TTTTTTTTTT
ATGCATCCTTCTAATCTCGCCCTCCAGCTTGTTCC-30; 50-CCCTTGAAAGG
GGCTTCTGGCGGGGGACCTC-30 ; 50-GAGGTCCCCCGCCAGAAGCCCCTTT
CAAGGG-30; 50-CTGCCCCGGCCTCAGGGGGGTGCTGATA-30; 50-TATCAG
CACCCCCCTGAGGCCGGGGCAG-30 . The following primers were used to
generate dsRNA targeting the 30-UTR of Amot: 50-TAATACGACTCACTATAGG
GTGTGTTTGGGGAGAAAAGGA-30 ; 50-TAATACGACTCACTATAGGGAAG
TCCAGGAAAAGGCCTGA-30 .
Embryo microinjection. Microinjection was performed on a Leica DM IRB with
attached Leica micromanipulators. Injections were administered via air pressure
using an Eppendorf Femtojet microinjector, and negative capacitance was used
to facilitate membrane penetration. All injections were carried out on embryos
suspended in M2 medium under parafﬁn oil on a depression slide. Successful
microinjections were conﬁrmed by the presence of ﬂuorescent markers co-injected
with the constructs. Ruby mRNA (0.4mgml 1) was co-injected for all
experiments except in the rescue experiments where 0.4mgml 1 Gap-RFP was
co-injected to mark the membrane without interfering with the cytoplasmic
Ruby introduced at the eight-cell stage.
qRT–PCR. RNA was extracted from embryos using the Arcturus PicoPure RNA
Isolation Kit. qRT–PCR was carried out using SYBR Green in a StepOne Plus
Real-time PCR machine (Applied Biosystems). Gapdh was used as an endogenous
control. The following primers were used: Gapdh 50-AGAGACGGCCGCATC
TTC-30 50-CCCAATACGGCCAAATCCGT-30 ; Amot 50-GATGTGCAACCCAGA
TAAGCC-30 50-TCTCTGCATCAGGCTCTTGC-30; Cdx2 50-AAACCTGTGCGA
GTGGATG-30 50-TCTGTGTACACCACCCGGTA-30 ; Eomes 50-CGGCCTACCA
AAACACGGAT-30 50-AAGCCGTGTACATGGAATCGTA-30; Gata3 50-CCGA
AACCGGAAGATGTCTA-30 50-AGATGTGGCTCAGGGATGAC-30 ; Oct4 50-TT
GGGCTAGAGAAGGATGTGGTT-30 50-GGAAAAGGGACTGAGTAGAGTGTG
G-30 ; Nanog 50-GGTTGAAGACTAGCAATGGTTCTGA-30 50-TGCAATGGAT
GCTGGGATACTC-30 ; Sox2 50-TGCTGCCTCTTTAAGACTAGGG-30 50-CGCC
GCGATTGTTGTGATT-30 ; Lats1 50-AACAAGTTCTTCCCGGAGCC-30 50-ACC
ATGTCCTCATCAAAGCCA-30 ; Lats2 50-GAATGCGGGATGTGACCAG-30
50-TACTCCAAGGCAGCTTCGAT-30 .
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